Close menu




October 23rd, 2020 | 14:36 CEST

Grenke, Delivery Hero, Desert Gold: Momentum shares on hold

  • Investments
Photo credits: pixabay.com

There are stocks where there is something in the air. For some of them, the trend is ultimately negative, others never pick up speed, and others just take off. Three of these potential momentum stocks are Grenke, Delivery Hero, and Desert Gold. At Grenke, the eyes of the market are focused on the accusations of balance sheet manipulation. Although the Baden-Baden-based Company has hired external auditors, suspended supervisory board posts, and announced a complete investigation, the share price is still not getting off the ground. For experienced investors, this means that something is coming to a head!

time to read: 3 minutes | Author: Nico Popp
ISIN: CA25039N4084 , DE000A161N30 , DE000A2E4K43

Table of contents:


    Grenke: Something is coming to a head!

    It is still unclear in which direction the share will ultimately go. However, it may make sense to take a closer look at the business in the first half of 2020. Initially, the Company was on record course before the outbreak of the pandemic. Then there was a significant slump, and towards the end of the first half of the year, the Company recovered. In July, Grenke already had new business, which was around 70% of the previous year's figure. When all signs of recovery were in place, the accusations followed. Since Grenke has opened new locations in recent months and the business has also survived the initial lockdown phase well, the signs for growth are good. Given the accusations and their complexity, however, private investors should wait with an investment in this potential momentum value until there are more facts about Grenke.

    Delivery Hero with lockdown potential

    The share of Delivery Hero has recently provided encouraging facts. In the first half of the year, the DAX stock achieved a sales growth of 87%. Given the lockdowns and the figures in other sectors, investors can rightly claim about the share: There is fire in it! But how sustainable is Delivery Hero's development? The Berlin-based Company has long since sold its German business and is focusing primarily on Asia and the Middle East. The Company is particularly well positioned in the latter region. Delivery Hero is paying for its rapid growth with losses. It remains to be seen whether the bet will work out for investors. On a one-year horizon, the share price has risen 120%, but it has been weakening recently.

    However, the positive development of the business in the first half of the crisis in 2020 could be a blueprint for further development. More and more countries are imposing lockdowns, examples being Ireland and the Czech Republic. The Middle East is also aware of the threat posed by the virus, and new lockdowns could be beneficial for Delivery Hero's figures. However, because of the continuing high valuation, it remains unclear whether the share will be able to pick up as much momentum as in the first half of the year.

    Team around gold share of the summer continues working

    One stock that is predestined to be a Momentum Stock is Desert Gold. On a one-year horizon, the share's price only shows a return of 2.4%, but between May and August alone, the share achieved a return of more than 100%. Desert Gold is exploring two promising gold projects with a strategic location in Mali. Among others, Barrick Gold, B2Gold, and Iamgold are active in the country. During the summer, good drill results ensured that the price quickly gained momentum.

    The Company's properties still show areas that offer further exploration potential. The Company is currently working on a 43-101 mining standard technical report and plans to publish it in the coming weeks. Desert Gold also plans to resume exploration work in November.

    Desert Gold: Risk appears manageable after price losses

    At a time when the pandemic is once again spreading, and states may be forced to support the economy, gold investments appear promising. While the gold price has recently stayed close to the highs, the Desert Gold share has fallen sharply. Such selling pressure can provide entry opportunities for smaller companies that have taken corporate actions in the past. Given the full coffers at Desert Gold, the promising projects, and the fundamentally strong situation for gold itself, the share could soon pick up speed again. Compared to, say, Delivery Hero, the valuation at the current level seems more attractive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read